SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 573.76 |
| Enterprise Value ($M) | 550.96 |
| Book Value ($M) | 352.48 |
| Book Value / Share | 10.97 |
| Price / Book | 1.63 |
| NCAV ($M) | 259.37 |
| NCAV / Share | 8.07 |
| Price / NCAV | 2.21 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.24 |
| Return on Assets (ROA) | -0.22 |
| Return on Equity (ROE) | -0.23 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 15.06 |
| Current Ratio | 15.22 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 280.90 |
| Assets | 374.01 |
| Liabilities | 21.53 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 6.24 |
| Operating Income | -101.86 |
| Net Income | -84.97 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -78.18 |
| Cash from Investing | -286.81 |
| Cash from Financing | 255.62 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Deep Track Capital, LP | 7.34 | ||
| 13D/A | Avidity Partners Management LP | 9.90 | 15.31 | |
| 13G/A | Ra Capital Management, L.p. | 9.40 | -4.28 | |
| 13G/A | BCLS Fund III Investments, LP | 8.80 | -10.10 | |
| 13G/A | Octagon Capital Advisors LP | 7.10 | 20.81 | |
| 13G | TCG Crossover GP II, LLC | 5.10 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 5.90 | 88.03 | |
| 13G/A | 5AM Partners VII, LLC | 3.50 | -38.92 | |
| 13G | BlackRock, Inc. | 5.60 | 0.00 | |
| 13D/A | Viridian, LLC | 3.72 | 0.00 | |
| 13D/A | Fairmount Funds Management LLC | 9.99 | -0.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 118,280 | 435,682 | 27.15 | |
| 126,123 | 907,970 | 13.89 | |
| 76,893 | 251,200 | 30.61 | |
| 65,721 | 283,358 | 23.19 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DARE – Daré Bioscience, Inc. | DERM – Journey Medical Corporation |
| DMAC – DiaMedica Therapeutics Inc. | DRMA – Dermata Therapeutics, Inc. |
| DRRX – DURECT Corporation |
Financial data and stock pages provided by
Fintel.io